Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ORGS | US
0.01
0.90%
Healthcare
Biotechnology
30/06/2024
09/03/2026
0.56
0.56
0.56
0.56
Orgenesis Inc. a biotech company focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown Maryland.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
237.3%1 month
1575.4%3 months
1332.4%6 months
10892.4%-
-
1.26
-0.84
0.43
-4.98
42.89
-
-19.06M
2.67M
2.67M
-
-1.65K
-
117.70
-727.25
2.39
1.33
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.30
Range1M
0.45
Range3M
0.60
Rel. volume
0.33
Price X volume
56.00
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Soligenix Inc | SNGX | Biotechnology | 1.2 | 2.74M | 0.84% | n/a | 84.28% |
| Sorrento Therapeutics Inc | SRNE | Biotechnology | 0.004 | 2.53M | -16.67% | n/a | -101.21% |
| PALISADE BIO INC | PALI | Biotechnology | 1.74 | 2.41M | 6.75% | n/a | 5.06% |
| Arsanis Inc | ASNS | Biotechnology | 0.3983 | 2.40M | 24.12% | n/a | 252.35% |
| Galera Therapeutics Inc | GRTX | Biotechnology | 0.04 | 2.22M | 0.00% | n/a | -0.87% |
| Dermata Therapeutics Inc. Common Stock | DRMA | Biotechnology | 1.33 | 2.01M | 6.40% | n/a | 0.00% |
| CARM | CARM | Biotechnology | 0.044 | 1.83M | 6.02% | n/a | 1044.17% |
| Allarity Therapeutics Inc. Common Stock | ALLR | Biotechnology | 1.24 | 1.75M | 0.00% | n/a | 6.68% |
| Plus Therapeutics Inc | PSTV | Biotechnology | 0.2952 | 1.74M | 2.25% | n/a | -45.04% |
| BioRestorative Therapies Inc | BRTX | Biotechnology | 0.232 | 1.61M | 8.97% | n/a | 0.77% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.46 | 1.36M | 2.93% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.008 | 737.72K | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -4.98 | 0.53 | Cheaper |
| Ent. to Revenue | 42.89 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.26 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 1,332.36 | 72.80 | Riskier |
| Debt to Equity | -0.84 | -1.23 | Expensive |
| Debt to Assets | 0.43 | 0.25 | Expensive |
| Market Cap | 2.67M | 3.66B | Emerging |